INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
On February 7, 2025, Swiss biopharmaceutical innovator BioVersys made its debut on the SIX Swiss Exchange, officially launching Switzerland’s IPO season for the year. With an opening share price of CHF 36.50, BioVersys reached a [...]
On the evening of April 9, 2025, The Voltahalle in Basel was the stage of [...]
AdjuTec Pharma AS - 3rd place winner of the Poster Competition at the 9th AMR [...]
INCATE kicked off the AMR week in Basel with the INCATE Networking Event on February [...]
Our colleague Helmut Kessmann has decided his time has come to retire and embark on new [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
